Herbert Irving Comprehensive Cancer Center
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Herbert Irving Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).
Herbert Irving Comprehensive Cancer Center: 11 sponsored US clinical trials, none currently recruiting.
Herbert Irving Comprehensive Cancer Center sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 2 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Leukemia, with 1 trials.
Top-decile sponsor footprint
Herbert Irving Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
11 total, page 1 of 1
G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete Remission
NCT00233961
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer
NCT00049452
Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy
NCT00055718
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis
NCT00007995
Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis
NCT00017680
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
NCT00007982
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Acute Leukemia
NCT00008190
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
NCT00008008
Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer
NCT00003124
Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix
NCT00003065
Comparison of Biological Therapies Following Combination Chemotherapy and Bone Marrow or Peripheral Stem Cell Transplantation in Women With Stage II or Stage III Breast Cancer
NCT00008203
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 8 |
| Phase 3 | 2 |
Therapeutic Areas
How the Herbert Irving Comprehensive Cancer Center early-phase archive is shaped
11 indexed studies, none listed as recruiting (0% open); 11 completed (100%).
Phase mix: 2 late (III/IV) vs 9 early (I/II) (early-phase heavy).
Top condition: Leukemia (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Herbert Irving Comprehensive Cancer Center: archived-pipeline peers nationwide
Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Herbert Irving Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 11 archived trials
- Aderans Research Institute · 11 trials · 0% recruiting
- Aegerion Pharmaceuticals · 11 trials · 0% recruiting
- Allena Pharmaceuticals · 11 trials · 0% recruiting
- AOBiome · 11 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Herbert Irving Comprehensive Cancer Center page
11 registered trials is a research-attention snapshot, not an endorsement of Herbert Irving Comprehensive Cancer Center or any single study.
- None of Herbert Irving Comprehensive Cancer Center's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Leukemia is the condition Herbert Irving Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Herbert Irving Comprehensive Cancer Center pipeline card: 11 registered trials from official public datasets.Report a data error.